Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

Beta 2 microglobulin in multiple myeloma.

Alexanian R, Barlogie B, Fritsche H.

Am J Hematol. 1985 Dec;20(4):345-51.

PMID:
3907332
2.

Serum beta-2-microglobulin in multiple myeloma: relation to presenting features and clinical status.

Bataille R, Magub M, Grenier J, Donnadio D, Sany J.

Eur J Cancer Clin Oncol. 1982 Jan;18(1):59-66.

PMID:
6177535
3.

[Prognostic importance of beta-2-microglobulin in multiple myeloma].

Avilés A, Zepeda G, Guzmán R, Talavera A, García EL, Díaz-Maqueo JC.

Rev Invest Clin. 1992 Apr-Jun;44(2):215-20. Spanish.

PMID:
1439309
4.

Clinical significance of correction of serum beta 2-microglobulin levels for serum creatinine in multiple myeloma.

Scudla V, Vavrdová V, Budíková M, Indrák K.

Acta Univ Palacki Olomuc Fac Med. 1991;131:257-64.

PMID:
1840347
5.

[The prognostic significance of the beta 2-microglobulin level of the blood serum in multiple myeloma patients].

Lubo-Lesnichenko IF, Bessmel'tsev SS, Abdulkadyrov KM, Blinov MN, Stel'mashenko LV.

Ter Arkh. 1996;68(10):28-31. Russian.

PMID:
9026938
6.

Pretreatment serum beta 2-microglobulin in multiple myeloma.

Brenning G, Simonsson B, Källander C, Ahre A.

Br J Haematol. 1986 Jan;62(1):85-93.

PMID:
3510657
7.

Prognostic significance of pretreatment serum beta 2-microglobulin levels in multiple myeloma.

Scarffe JH, Anderson H, Palmer MK, Crowther D.

Eur J Cancer Clin Oncol. 1983 Oct;19(10):1361-4.

PMID:
6357802
8.

Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.

Bataille R, Durie BG, Grenier J.

Br J Haematol. 1983 Nov;55(3):439-47.

PMID:
6357266
9.

[Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].

Scudla V, Budíková M, Fischerová E, Raska I, Vavrdová V.

Vnitr Lek. 1991 May;37(5):479-87. Czech.

PMID:
1842146
10.

Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study.

Durie BG, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman CA.

Blood. 1990 Feb 15;75(4):823-30.

11.

Serum beta 2-microglobulin: a real improvement in the management of multiple myeloma?

van Dobbenburgh OA, Rodenhuis S, Ockhuizen T, Weltevreden E, Houwen B, Fidler V, Meijer S, Marrink J.

Br J Haematol. 1985 Dec;61(4):611-20.

PMID:
3910076
12.

[Prognostic value of serum beta2-microglobulin in multiple myeloma].

Bettini R, Redaelli S, Maino C, Bertuol S, Costantini C, Lazzarini A, Brivio L, Gorini M.

Recenti Prog Med. 2005 Feb;96(2):81-6. Italian.

PMID:
15844767
13.

[Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma].

Bataille R, Grenier J.

Presse Med. 1986 Oct 11;15(34):1723-5. Review. French.

PMID:
2947132
15.

Prognostic factors and staging in multiple myeloma: a reappraisal.

Bataille R, Durie BG, Grenier J, Sany J.

J Clin Oncol. 1986 Jan;4(1):80-7.

PMID:
3510284
16.

Therapeutic implications of myeloma staging.

Durie BG, Bataille R.

Eur J Haematol Suppl. 1989;51:111-6. Review.

PMID:
2697583
18.

Additional predictive value of serum unsaturated vitamin B12 proteins in multiple myeloma.

Arnalich F, Zamorano AF, Martinez-Hernández P, Pena JM, Barbado FJ, Vázquez JJ.

J Med. 1990;21(5):277-86.

PMID:
2079617
19.

Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.

Bataille R, Grenier J, Sany J.

Anticancer Res. 1987 May-Jun;7(3 Pt B):513-5.

PMID:
3307602
20.

Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders.

Garewal H, Durie BG, Kyle RA, Finley P, Bower B, Serokman R.

J Clin Oncol. 1984 Jan;2(1):51-7.

PMID:
6366146
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk